STOCK TITAN

Vertex (VRTX) Form 144 Notice — 266 Shares Scheduled for Sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Vertex Pharmaceuticals (VRTX) Form 144 notice: An individual filer intends to sell 266 shares of Vertex common stock through Fidelity Brokerage Services on the NASDAQ, with an aggregate market value of $102,859.54 and approximately 256,390,651 shares outstanding. The securities were acquired on May 1, 2024 via restricted stock vesting from the issuer and were paid as compensation on the same date. The approximate sale date is listed as August 27, 2025. The filer reports no other sales in the past three months and affirms no undisclosed material adverse information.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Small insider sale in absolute terms; unlikely to be material to VRTX but noteworthy as a scheduled Rule 144 disposition.

The filing documents a planned off-exchange sale under Rule 144 of 266 vested restricted shares, valued at about $102.9k, executed through Fidelity and scheduled for August 27, 2025. Given the issuer's outstanding share count (~256.4 million), this represents an immaterial dilution percentage and is routine for insiders disposing of vested compensation. No prior sales in the past three months were reported, and the filer certifies lack of undisclosed material information. Impact on market valuation is likely negligible.

TL;DR: The Form 144 appears compliant: acquisition, nature, payment, broker, and intended sale date are disclosed.

The notice provides the required Rule 144 elements: acquisition date (05/01/2024), nature of acquisition (restricted stock vesting), consideration (compensation), broker details, number of shares, aggregate market value, and planned sale date. The filer signed the standard representation regarding material nonpublic information and reported no sales in the prior three months. From a compliance perspective, the filing meets disclosure expectations for a standard Rule 144 sale.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the VRTX Form 144 disclose about the planned sale?

The notice discloses a planned sale of 266 shares of Vertex common stock through Fidelity on NASDAQ with aggregate market value of $102,859.54, approximate sale date 08/27/2025.

How and when were the shares being sold acquired according to the filing?

The shares were acquired on 05/01/2024 through restricted stock vesting from the issuer and were paid as compensation on that date.

Does the Form 144 report any other sales by the filer in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

What broker is handling the proposed sale in the Form 144?

The broker listed is Fidelity Brokerage Services LLC at the address provided (900 Salem Street, Smithfield, RI 02917).

What representation does the filer make about material information?

By signing, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.